TG Therapeutics, Inc. (NASDAQ:TGTX – Get Free Report) saw unusually large options trading activity on Monday. Stock traders acquired 8,465 call options on the stock. This is an increase of approximately 46% compared to the average daily volume of 5,801 call options.
Wall Street Analysts Forecast Growth
A number of research analysts have commented on the company. StockNews.com raised TG Therapeutics from a “sell” rating to a “hold” rating in a report on Tuesday, March 4th. HC Wainwright reissued a “buy” rating and set a $55.00 target price on shares of TG Therapeutics in a research note on Tuesday, March 4th. Two equities research analysts have rated the stock with a hold rating and four have given a buy rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $40.80.
View Our Latest Analysis on TGTX
TG Therapeutics Stock Performance
TG Therapeutics (NASDAQ:TGTX – Get Free Report) last posted its quarterly earnings data on Wednesday, May 7th. The biopharmaceutical company reported $0.03 earnings per share for the quarter, missing the consensus estimate of $0.19 by ($0.16). TG Therapeutics had a negative return on equity of 8.32% and a negative net margin of 5.42%. The company’s revenue was up 90.4% on a year-over-year basis. During the same quarter in the previous year, the firm earned ($0.07) EPS. As a group, equities analysts predict that TG Therapeutics will post 0.08 EPS for the current fiscal year.
Hedge Funds Weigh In On TG Therapeutics
Several institutional investors and hedge funds have recently modified their holdings of TGTX. Vanguard Group Inc. increased its stake in shares of TG Therapeutics by 1.4% during the 4th quarter. Vanguard Group Inc. now owns 15,596,480 shares of the biopharmaceutical company’s stock worth $469,454,000 after purchasing an additional 209,190 shares during the last quarter. Soleus Capital Management L.P. boosted its position in shares of TG Therapeutics by 5.8% in the fourth quarter. Soleus Capital Management L.P. now owns 2,681,242 shares of the biopharmaceutical company’s stock valued at $80,705,000 after acquiring an additional 146,702 shares during the period. Clearbridge Investments LLC bought a new stake in shares of TG Therapeutics in the fourth quarter valued at about $55,237,000. Northern Trust Corp raised its stake in shares of TG Therapeutics by 8.6% in the fourth quarter. Northern Trust Corp now owns 1,532,929 shares of the biopharmaceutical company’s stock valued at $46,141,000 after purchasing an additional 120,785 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. lifted its holdings in shares of TG Therapeutics by 7.2% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 1,269,513 shares of the biopharmaceutical company’s stock worth $38,212,000 after acquiring an additional 84,904 shares during the period. 58.58% of the stock is currently owned by hedge funds and other institutional investors.
About TG Therapeutics
TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.
Read More
- Five stocks we like better than TG Therapeutics
- Profitably Trade Stocks at 52-Week Highs
- Monster Beverage Stock: Short Report Risks vs Upside Potential
- REIT Stocks – Best REIT Stocks to Add to Your Portfolio Today
- Onsemi Stock Confirms Bottom, But What’s the Upside?
- How to Short a Stock in 5 Easy Steps
- 3 Tech Leaders Announce Buybacks Totaling $85 Billion
Receive News & Ratings for TG Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TG Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.